About US
Contact us
-
Feds say Astellas, Amgen will fork over $125M to settle charity kickback probesThe Justice Department has swept pharma companies large and small into an investigation examining the ties between drugmakers and patient charities, and now two more—Astellas and Amgen—haveinkedset2019/4/26
-
Good news for AZ's 'next phase of growth': Its cancer drugs have shifted into high gearFor the first time, AstraZeneca's top-selling medicine isn't a stomach drug or a respiratory inhaler or any other primary care med. It's a cancer drug.That would be Tagrisso, the EGFR inhibitor for l2019/4/26
-
FiercePharmaAsia—Lilly China asset sale; Daiichi's bispecific I-O deal; Torrent 1M-bottle sartan recallJoining its Big Pharma peers in selling legacy brands in China to focus on newer, innovative therapies, Eli Lilly decided to cast off two decades-old antibiotic brands in the country. With a renewed2019/4/25
-
BMS' head and neck cancer hopes take a hit with Opdivo-Yervoy trial flopBristol-Myers Squibb already has one Opdivo approval in previously treated head and neck cancer, but it won’t make that two. The company, which was testing its immuno-oncology star alongside Yervoy i2019/4/25
-
Lilly’s Taltz meets endpoints in Phase III study for nr-axSpAGlobal pharmaceutical company Eli Lilly has announced top line results for Taltz (ixekizumab) in non-radiographic axial spondyloarthritis (nr-axSpA). The drug met its primary and secondary endpoints2019/4/24
-
Merck’s Keytruda gets FDA approval to treat kidney cancerMerck has received US Food and Drug Administration (FDA) approval for its anti-PD-1 therapy Keytruda to treat advanced renal cell carcinoma (RCC) patients. The approval allows the drug to be used in2019/4/24
-
Federal judge scolds Purdue, Endo and Mallinckrodt for stall tactics in opioids caseU.S. District Judge Dan Polster has had enough of opioids makers Purdue Pharma, Endo and Mallinckrodt asking for extensions in the multistate lawsuit against them. And he said as much Thursday in the2019/4/23
-
Bausch Health is far from the LeBron James in eye care, so don't compare it to Alcon: analystAfter Novartis eye care spinoff Alcon made a successful debut on the Swiss Exchange earlier this month, some analysts used it as an argument to make a bullish case for Bausch Health. But one analyst2019/4/23
-
Gorsky says military service had 'profound effect' on his reign as J&J chiefWhat does it take to steer one of pharma’s biggest whales? As Johnson & Johnson CEO Alex Gorsky told Fortune magazine, six years in the U.S. Army made all the difference. Gorsky, the $20-million-2019/4/22
-
Roche throws in the towel on Tecentriq bladder, myeloma trialsRoche’s Tecentriq has scored some important victories lately, including a pair of first-in-class approvals. But in other types of cancer, the Swiss drugmaker has decided to pull the plug. In a Wednes2019/4/22